These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
TransMedics said it continued to expect full-year revenue to be in the range of $425 million to $445 million versus estimates of $444.36 million.TransMedics Group, Inc. (NASDAQ:TMDX) posted downbeat quarterly results on Monday.
transmedics集團（納斯達克股票代碼：TMDX）週一發佈了令人失望的季度業績。
TransMedics reported quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 30 cents per share. The company reported quarterly sales of $108.76 million which missed the analyst consensus estimate of $115.00 million.
TransMedics報告每股12美分的季度收益，低於分析師共識預期的30美分。該公司報告的季度銷售額爲10876萬美元，低於分析師共識預期的11500萬美元。
"We are proud of our performance year to date and look forward to ending 2024 on a strong note," said Waleed Hassanein, president and CEO of TransMedics. "We continued to make meaningful progress across each of our growth initiatives through the third quarter and maintain our conviction in our growth runway for 2025 and beyond."
「我們爲今年以來的表現感到自豪，並期待在2024年結束時取得強勁的業績。」transmedics總裁兼首席執行官瓦利德·哈桑尼（Waleed Hassanein）表示，「我們在第三季度在每個增長計劃中繼續取得顯著進展，並堅定地相信我們在2025年及以後的增長道路。」
TransMedics said it continued to expect full-year revenue to be in the range of $425 million to $445 million versus estimates of $444.36 million.
transmedics表示，他們預計全年營業收入將在42500萬至44500萬美元的區間內，而市場預估爲44436萬美元。
TransMedics shares gained 0.9% to close at $126.24 on Monday.
週一，transmedics股價上漲0.9%，收於126.24美元。
These analysts made changes to their price targets on TransMedics following earnings announcement.
這些分析師根據收益公告對transmedics的目標價進行了調整。
- Needham analyst Mike Matson maintained TransMedics with a Buy and lowered the price target from $208 to $109.
- Baird analyst Joe Vruwink maintained the stock with an Outperform and lowered the price target from $200 to $150.
- Canaccord Genuity analyst Jason Mills maintained TransMedics with a Buy and lowered the price target from $169 to $109.
- Needham分析師邁克·馬森（Mike Matson）維持對transmedics的買入評級，將目標價從208美元降至109美元。
- Baird分析師喬·弗魯溫克（Joe Vruwink）維持該股的跑贏大盤評級，將目標價從200美元降至150美元。
- Canaccord Genuity分析師Jason Mills維持買入評級，將目標價從169美元降至109美元。
Considering buying TMDX stock? Here's what analysts think:
考慮購買transmedics股票？以下是分析師的看法：
Read More:
閱讀更多：
- Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
- 道指暴漲逾250點，迎來谷歌母公司和輝瑞發佈業績：投資者情緒改善，恐慌指數仍處於'貪婪'區域
譯文內容由第三人軟體翻譯。
